Bedaquiline and multidrug-resistant tuberculosis: A systematic and critical analysis of the evidence

European Respiratory Journal

Volumn 47, Issue 2, 2016, Pages 394-402

  Pontali, Emanuele ^a   Sotgiu, Giovanni ^b   D'Ambrosio, Lia ^c,d   Centis, Rosella ^c   Migliori, Giovanni Battista ^c  

^a GALLIERA HOSPITAL   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

^c IRCCS   (Italy)

^d Public Health Consulting Group SAGL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

HUMAN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; HUMANS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84958093367     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01891-2015     Document Type: Review

References (70)

1. World Health Organization. Global Tuberculosis Report 2015. 20th Edn. Geneva, World Health Organization, 2015.
2. Sotgiu G, Mauch V, Migliori GB, et al. Evidence-based, agreed-upon health priorities to remedy the tuberculosis patient's economic disaster. Eur Respir J 2014; 43: 1563-1566.
3. Lönnroth K, Migliori GB, Abubakar I, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J 2015; 45: 928-952.
4. Diel R, Loddenkemper R, Zellweger JP, et al. Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination. Eur Respir J 2013; 42: 785-801.
5. D'Ambrosio L, Dara M, Tadolini M, et al. Tuberculosis elimination: theory and practice in Europe. Eur Respir J 2014; 43: 1410-1420.
6. Migliori GB, Lienhardt C, Weyer K, et al. Ensuring rational introduction and responsible use of new TB tools: outcome of an ERS multisector consultation. Eur Respir J 2014; 44: 1412-1417.
7. Skrahina A, Hurevich H, Zalutskaya A, et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 2012; 39: 1425-1431.
8. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42: 169-179.
9. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012; 9: e1001300.
10. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42: 156-168.
11. Pontali E, Matteelli A, Migliori GB. Drug resistant tuberculosis. Curr Opin Pulm Med 2013; 19: 266-272.
12. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-528.
13. World Health Organization. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Document N. WHO/HTM/TB/2014.11. Geneva, World Health Organization, 2014.
14. Seddon JA, Godfrey-Faussett P, Jacobs K, et al. Hearing loss in patients on treatment for drug-resistant tuberculosis. Eur Respir J 2012; 40: 1277-1286.
15. Isaakidis P, Varghese B, Mansoor H, et al. Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India. PLoS One 2012; 7: e40781.
16. Pontali E, Sotgiu G, Centis R, et al. Management of drug resistant TB in patients with HIV co-infection. Expert Opin Pharmacother 2015 [in press; DOI:10.1517/14656566.2015.1100169].
17. Esposito S, Bianchini S, Blasi F. Bedaquiline and delamanid in tuberculosis. Expert Opin Pharmacother 2015; 16: 2319-2330.
18. Migliori GB, Eker B, Richardson MD, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009; 34: 387-393.
19. Villar M, Sotgiu G, D'Ambrosio L, et al. Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis. Eur Respir J 2011; 38: 730-733.
20. De Lorenzo S, Centis R, D'Ambrosio L, et al. On linezolid efficacy and tolerability. Eur Respir J 2012; 39: 770-772.
21. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-1442.
22. Sotgiu G, Centis R, D'Ambrosio L, et al. Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence. Eur Respir J 2013; 42: 288-290.
23. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012; 367: 1508-1518.
24. Sotgiu G, Centis R, D'Ambrosio L, et al. Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains. Eur Respir J 2015; 45: 287-289.
25. Sotgiu G, Pontali E, Migliori GB. Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios. Eur Respir J 2015; 45: 25-29.
26. De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J 2013; 41: 1386-1392.
27. Tiberi S, D'Ambrosio L, De Lorenzo S, et al. Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience. Eur Respir J 2016; 47: 177-185.
28. Tiberi S, D'Ambrosio L, De Lorenzo S, et al. Tuberculosis elimination, patients' lives and rational use of new drugs: revisited. Eur Respir J 2015; 47: 664-667.
29. Alsaad N, Wilffert B, van Altena R, et al. Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis. Eur Respir J 2014; 43: 884-897.
30. Alsaad N, van Altena R, Pranger AD, et al. Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis. Eur Respir J 2013; 42: 504-512.
31. Krieger D, Vesenbeckh S, Schönfeld N, et al. Mefloquine as a potential drug against multidrug-resistant tuberculosis. Eur Respir J 2015; 46: 1503-1505.
32. Sotgiu G, Pontali E, Centis R, et al. Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis. Expert Rev Anti Infect Ther 2015; 13: 305-315.
33. Caminero JA, Scardigli A. Classification of antituberculosis drugs: a new proposal based on the most recent evidence. Eur Respir J 2015; 46: 887-893.
34. Salfinger M, Migliori GB. Bedaquiline: 10 years later, the drug susceptibility testing protocol is still pending. Eur Respir J 2015; 45: 317-321.
35. Salfinger M, Migliori GB. Bedaquiline: finding the pores on the pot. Eur Respir J 2015; 46: 289-291.
36. Tiberi S, De Lorenzo S, Centis R, et al. Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use. Eur Respir J 2014; 43: 289-292.
37. van Halsema C, Humphreys S, Bonington A. Extensively drug-resistant tuberculosis: early access to bedaquiline for a UK patient. Eur Respir J 2014; 43: 292-294.
38. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 2013; 41: 1393-1400.
39. Blasi F, Dara M, van der Werf MJ, et al. Supporting TB clinicians managing difficult cases: the ERS/WHO Consilium. Eur Respir J 2013; 41: 491-494.
40. D'Ambrosio L, Tadolini M, Dupasquier S, et al. ERS/WHO tuberculosis consilium: reporting of the initial 10 cases. Eur Respir J 2014; 43: 286-289.
41. Esposito S, D'Ambrosio L, Tadolini M, et al. ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. Eur Respir J 2014; 44: 811-815.
42. D'Ambrosio L, Tadolini M, Centis R, et al. Supporting clinical management of the difficult-to-treat TB cases: the ERS-WHO TB Consilium. Int J Infect Dis 2015; 32: 156-160.
43. D'Ambrosio L, Tadolini M, Centis R, et al. A new free-cost e-service supporting clinicians to manage their difficult-to-treat TB cases: the ERS-WHO TB Consilium. J Thorac Dis 2015; 7: 1080-1085.
44. Reed C, Mason L, Cox H, et al. Compassionate and optimum use of new tuberculosis drugs. Lancet Infect Dis; 15: 1131.
45. Matteelli A, D'Ambrosio L, Centis R, et al. Compassionate and optimum use of new tuberculosis drugs. Lancet Infect Dis; 15: 1131-1132.
46. Pym AS, Diacon AH, Tang S-J, et al. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J 2016; 47: 564-574.
47. Pontali E, Centis R, D'Ambrosio L, et al. Monitoring predictors of mortality: a necessary action to reach TB elimination causes of death and death-related risk factors. Rev Port Pneumol 2015 [in press; DOI: 10.1016/j. rppnen.2015.10.007].
48. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307: 223-227.
49. Koul A, Dendouga N, Vergauwen K, et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol 2007; 3: 323-324.
50. World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Interim policy guidance. Geneva, World Health Organization, 2013.
51. Diacon AH, Dawson R, Von Groote-Bidlingmaier F, et al. Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis. Antimicrob Agents Chemother 2013; 57: 2199-2203.
52. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397-2405.
53. Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 371: 723-732.
54. Lienhardt C, Raviglione M, Spigelman M, et al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis 2012; 205: Suppl. 2, S241-S249.
55. U.S. Food and Drug Administration. Expanded Access (Compassionate Use). www.fda.gov/NewsEvents/PublicHealthFocus/ExpandedAccessCompassionateUse/ucm20080392.htm Date last accessed: November 12, 2015. Date last updated: November 19, 2015.
56. European Medicines Agency. Human medicines: regulatory information. www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/landing/human-medicines-regulatory.jsp Date last accessed: November 12, 2015.
57. European Medicines Agency, Committee for medicinal products for human use (CHMP). Guideline on compassionate use of medicinal products, pursuant to article 83 of regulation (EC) No 726/20004. www.ema.europa.eu/docs/en-GB/document-library/Regulatory-and-procedural-guideline/2009/10/WC500004075.pdf Date last accessed: November 12, 2015. Date last updated: July 19, 2007.
58. Guglielmetti L, Le Dû D, Jachym M, et al. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis 2015; 60: 188-194.
59. Ndjeka N, Conradie F, Schnippel K, et al. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. Int J Tuberc Lung Dis 2015; 19: 979-985.
60. Annex I. Summary of product characteristics. Sirturo 100 mg tablets. www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002614/WC500163209.pdf Date last accessed: December 15, 2015.
61. World Health Organization. The use of delamanid in the treatment of multidrug-resistant tuberculosis. Interim policy guidance. Geneva, World Health Organization, 2014.
62. World Health Organization. Policy implementation package for new TB drug introduction. Geneva, World Health Organization, 2014.
63. Petrella S, Cambau E, Chauffour A, et al. Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria. Antimicrob Agents Chemother 2006; 50: 2853-2856.
64. Hartkoorn RC, Uplekar S, Cole ST. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014; 58: 2979-2981.
65. Gupta S, Cohen KA, Winglee K, et al. Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014; 58: 574-576.
66. Centers for Disease Control and Prevention. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. www.cdc.gov/mmwr/preview/mmwrhtml/rr6209a1.htm Date last accessed: November 12, 2015. Date late updated: October 25, 2013.
67. International Union Against Tuberculosis and Lung Disease. Current Trials: STREAM clinical trial to test first all-oral MDR-TB treatment regimen. www.theunion.org/what-we-do/research/clinical-trials Date last accessed: November 12, 2015.
68. Nunn AJ, Rusen ID, Van Deun A, et al. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials 2014; 15: 353.
69. UNITAID. UNITAID Approves Grants of $160 million. www.unitaid.org/en/resources/press-centre/releases/1352-unitaid-approves-grants-of-160-million Date last accessed: November 12, 2015. Date last updated: May, 6 2014.
70. Getahun H, Matteelli A, Abubakar I, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J 2015; 46: 1563-1576.